# Bit Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bit-bio

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.bit.bio
- Total disclosed funding: $255M
- Latest round: Series D (Nov 4, 2026)
- Investors on record: 13

## About

Bit Bio Ltd., based in the UK, is a biomedical company focused on synthetic biology solutions, particularly specializing in engineered human induced pluripotent stem cells for research and therapeutic applications. Bit Bio Ltd. operates in the field of synthetic biology, developing precision-engineered human cells. Founded in 2016 in Cambridge, UK, the company was established by Mark Kotter. Bit Bio Ltd specializes in the development and production of synthetic biology solutions, particularly through their flagship product, ioCells, which consists of deterministically programmed human induced pluripotent stem cell (iPSC)-derived cells. These cells are engineered for precision and consistency, enabling them to serve various applications in research and drug discovery. The company also offers a range of specialized cells, including ioDisease Model Cells designed for specific conditions like Alzheimer's disease and ALS, and CRISPR-ready ioCells, facilitating advanced genomic interventions. Bit Bio targets a diverse client base, including academic institutions, biopharmaceutical companies, and research organizations globally, particularly in the United States, Europe, and Asia, where there is a strong demand for innovative cell-based therapies and research tools. Bit Bio generates revenue through direct sales of its specialized cell products and services to institutional clients, including research facilities and pharmaceutical companies. For the year 2023, the company reported a revenue of GBP 6,077,867.10, with an EBITDA of GBP -58,406,486.40. 

The transaction structure primarily involves business-to-business (B2B) interactions, where clients place orders for specific cell types or custom solutions tailored to their research needs. The company plans to launch new products that enhance its offerings in the near future, while expanding its market presence specifically targeting North America, Europe, and Asia by 2025. In December 2025, Bit Bio Ltd. raised USD 50 million in series C funding led by M&G and other investors include Puhua Capital, Milky Way Ventures, ARCH Venture Partners, BlueYard Capital and Tencent Investment. The company will use the funding to accelerate development of its human cell programming products, expand global operations, strengthen manufacturing capabilities, and build datasets for artificial intelligence model training.

## Funding rounds

- Series D, Nov 4, 2026, $25M — Dr. Jonathan Milner, Jonathan Milner, M&G Investments
- Series C, Dec 29, 2025, $50M — ARCH Venture Partners, M&G, Puhua Capital, BlueYard Capital, Milky Way Ventures, Tencent Investment
- Series B, Dec 31, 2021, $37M — ARCH Venture Partners
- Series B, Sep 30, 2021, $104M — ARCH Venture Partners, Tencent Investment, Foresite Capital, National Resilience, LLC., Puhua Capital, Charles River Laboratories, Metaplanet Holdings
- Series A, Jun 9, 2020, $39M — ARCH Venture Partners, Foresite Capital, BlueYard Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B
- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Series A, Series C
- Tencent Investment — Series B, Series C
- National Resilience, LLC. — Series B
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series B, Series C
- Charles River Laboratories — Series B
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Series B
- M&G (https://capitalatlas.ai/funds/m-g) — Series C
- Milky Way Ventures (https://capitalatlas.ai/funds/milky-way-ventures) — Series C
- Dr. Jonathan Milner — Series D
- Jonathan Milner — Series D
- M&G Investments — Series D